Research Topics
Species | Carlo Gambacorti-PasseriniSummaryAffiliation: University of Milano-Bicocca Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Part I: Milestones in personalised medicine--imatinibCarlo Gambacorti-Passerini
Clinical Research Unit, University of Milano Bicocca, San Gerardo Hospital, Monza, Italy
Lancet Oncol 9:600. 2008- Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinibCarlo Gambacorti-Passerini
Professor of Internal Medicine and OncologyNCI/University of Milano Bicocca, Italy and JGH, McGill University, Montreal, Canada
Haematologica 90:434. 2005 - Prognostic variables in patients with chronic myeloid leukemia treated with imatinibCarlo Gambacorti-Passerini
University of Milano Bicocca, Monza, Italy
Haematologica 91:145a. 2006 
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinibCarlo Gambacorti-Passerini
Hematology and Clinical Research Unit, San Gerardo Hospital, Italy
J Natl Cancer Inst 103:553-61. 2011..Imatinib slows development of chronic myeloid leukemia (CML). However, available information on morbidity and mortality is largely based on sponsored trials, whereas independent long-term field studies are lacking...- The ALK gene, an attractive target for inhibitor developmentCarmen J Tartari
Department of Clinical Medicine, University of Milano Bicocca, Italy
Curr Top Med Chem 11:1406-19. 2011..Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity... 
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylationAddolorata Maria Luce Coluccia
Department of Clinical Medicine, University of Milano Bicocca, Monza, Milan, Italy
EMBO J 26:1456-66. 2007..These findings indicate the Bcr-Abl triggered Y phosphorylation of beta-catenin as a new mechanism responsible for its protein stabilization and nuclear signalling activation in CML...- Valproic acid enhances bosutinib cytotoxicity in colon cancer cellsLuca Mologni
Department of Clinical Medicine and Prevention, University of Milano Bicocca, Monza, Italy
Int J Cancer 124:1990-6. 2009..These results suggest that VPA may be employed as a positive modulator of bosutinib antitumor activity in colorectal cancer... - Expression, purification, and inhibition of human RET tyrosine kinaseLuca Mologni
Department of Clinical Medicine, University of Milano Bicocca, Monza, Italy
Protein Expr Purif 41:177-85. 2005..These reagents were used to develop a rapid ELISA-based kinase assay for screening potential inhibitors. Novel RET inhibitors were identified using this assay... - Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitorsSara Redaelli
Department of Clinical Medicine and Prevention, University of Milano Bicocca, S Gerardo Hospital, Monza, Milan, Italy
Am J Hematol 87:E125-8. 2012..The availability of drugs activity profiles may become a useful tool for clinicians dealing with the treatment of drug-resistant CML patients... - In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cellsMiriam Puttini
Department of Clinical Medicine, S. Gerardo Hospital-University of Milano-Bicocca, Monza, Italy
Cancer Res 66:11314-22. 2006..Modeling considerations attribute the superior activity of SKI-606 to its ability to bind a conformation of Bcr-Abl different from imatinib... - Inhibition of RET tyrosine kinase by SU5416Luca Mologni
Department of Clinical Medicine, Prevention and Biotechnology, University of Milan Bicocca, Monza, Italy
J Mol Endocrinol 37:199-212. 2006..We provide a possible explanation to these results by using molecular docking. Finally, SU5416 was also assessed against an array of 52 tyrosine and serine/threonine kinases... - Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylatePaolo Perseghin
Department of Clinical Pathology Immunohematology and Transfusion Service, Therapeutic Apheresis Unit, San Gerardo de Tintori Hospital, Monza, Italy
Transfusion 45:1214-20. 2005..Nevertheless, some concerns exist about the duration of response to treatment and the onset of resistance to IM... - Recurrent SETBP1 mutations in atypical chronic myeloid leukemiaRocco Piazza
Department of Health Sciences, University of Milano Bicocca, Monza, Italy
Nat Genet 45:18-24. 2013..In summary, mutated SETBP1 represents a newly discovered oncogene present in aCML and closely related diseases... - Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinaseCarmen J Tartari
Department of Clinical and Prevention Medicine, University of Milano Bicocca, Via Cadore 48, Monza 20052, Italy
J Biol Chem 283:3743-50. 2008..Together, our findings indicate that phosphorylation of the first tyrosine of the YXXXYY motif is necessary for the autoactivation of the ALK kinase domain and the transforming activity of NPM/ALK... - ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cellsVera Magistroni
Department of Clinical Medicine, University of Milano Bicocca, Monza, Italy
PLoS ONE 6:e28162. 2011..Here we provide the first evidence for an ERG-mediated PIM1 up-regulation in prostate cells in vitro and in vivo, suggesting a direct effect of ERG transcriptional activity in the alteration of genetic stability... - Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modelingRosalind H Gunby
Department of Clinical Medicine, University of Milano-Bicocca, Monza, 20052, Italy
J Med Chem 49:5759-68. 2006..In addition, 4-phenylamino-quinoline compounds may have potential as templates for ALK inhibitors... - Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapyRosalind H Gunby
Department of Clinical Medicine, University of Milano Bicocca, Monz, Italy
Anticancer Agents Med Chem 7:594-611. 2007..Here we review the PTKs known to be expressed as FTKs in cancer and the strategies for molecularly targeting these FTKs in anti-cancer therapy... - The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 yearsRocco G Piazza
University of Milano Bicocca, S. Gerardo Hospital, Monza, Italy
Blood Cells Mol Dis 37:111-5. 2006..0001). This 6-year follow-up of the efficacy of Imatinib therapy in CML patients who obtained a durable CCyR indicates that the relapses rate is low over this period of observation and that the rate of relapse does not increase over time... - NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphomaAnnamaria Galietta
Department of Clinical Medicine, University of Milano Bicocca, Monza, Italy
Blood 110:2600-9. 2007..These results identify PSF as a novel NPM/ALK-binding protein and substrate, and suggest that PSF function may be perturbed in NPM/ALK-transformed cells... - BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cellsElisa Sala
University of Milano Bicocca, Via Cadore 48, Monza, 20052 Italy
Mol Cancer Res 6:751-9. 2008..Furthermore, we suggest that a BRAF-independent mechanism of cell survival exists in anaplastic thyroid cancer cells... - Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitorsLuca Mologni
Department of Clinical Medicine and Prevention, University of Milano Bicocca, Monza, Italy
Bioorg Med Chem 18:1482-96. 2010..Crystallographic analysis confirmed predictions from molecular modelling and helped refine SAR results. These data provide important information for the development of indolinone inhibitors for the treatment of RET-driven cancers... - A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancerElisa Sala
Department of Experimental Oncology, National Cancer Institute, Milan, Italy
Int J Biol Macromol 39:60-5. 2006.... - Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitorsMonica Ceccon
Department of Health Sciences, University of Milano Bicocca, Via Cadore 48, Monza 20900, Italy
Mol Cancer Res 11:122-32. 2013..This study provides potentially relevant information for the management of patients with ALCL that may relapse after crizotinib treatment... - FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discoveryRocco Piazza
Department of Clinical Medicine, University of Milano Bicocca, Monza, 20900, Italy
Nucleic Acids Res 40:e123. 2012..Therefore, we propose FusionAnalyser as an efficient and robust graphical tool for the identification of functional rearrangements in the context of high-throughput transcriptome sequencing data... - Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cellsLuca Mologni
Department of Health Sciences, University of Milano Bicocca, Monza, Italy
PLoS ONE 7:e51449. 2012..Expression analysis of selected cancer-relevant genes revealed down-regulation of CD44 as a common response to the combined treatments. These data provide a proof of principle for a combination therapeutic strategy in colorectal cancer... - Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual diseaseAnna Franceschino
University of Milano Bicocca, Section of Hematology, Ospedale S.Gerardo, Via Cadore 48, 20052 Monza, Italy
Haematologica 91:ECR14. 2006 - The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsMichael W N Deininger
Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA
Cancer 110:1509-19. 2007..In some patients, CCA/Ph-negative status was associated with myelodysplasia or acute myeloid leukemia. The objective of the current study was to determine the prognostic impact of CCA/Ph-negative cells... - FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemiaPaolo Neviani
Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA
J Clin Invest 117:2408-21. 2007..Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients... - A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer targetAya Wakata
Department of Biochemistry, The Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, New York 10461, USA
Org Lett 10:301-4. 2008.... - Characterization of compound 584, an Abl kinase inhibitor with lasting effectsMiriam Puttini
School of Pharmaceutical Sciences, University of Geneva, Quai Ernest Ansermet 30, 1211 Geneve 4, Switzerland
Haematologica 93:653-61. 2008..In the current study we describe the design, synthesis and biological properties of an imatinib analog with a chlorine-substituted benzamide, namely compound 584 (cmp-584)... - Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinibAddolorata Maria Luce Coluccia
Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
Blood 112:1346-56. 2008..Overall data highlight the biologic and therapeutic relevance of the combined targeting of PDGFRbeta/c-Src TKs in MM, providing a framework for future clinical trials... - Decrease of resistance to imatinib in leukaemiaCarlo Gambacorti-Passerini
Lancet 359:1777. 2002 - Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinibAnna Franceschino
Haematologica 93:317-8. 2008..We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values... - In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'Carlo Gambacorti-Passerini
Nat Med 13:13-4; author reply 15-6. 2007 - BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin BAlessandra Aloisi
Department of Biomedical Sciences, Section of General Pathology, University of Catania, Via Androne, 83-95124 Catania, Italy
Blood 107:1591-8. 2006.... - Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cellsHolger Ruchatz
The National Cancer Institute, Oncogenic Fusion Proteins Unit, Department of Experimental Oncology, Milan, Italy
Exp Hematol 31:309-15. 2003..Jak/Stat signaling is aberrantly activated in several human hematopoietic malignancies. We investigated the role of Jak2 in the context of NPM/ALK-mediated oncogenesis... - Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemiaRosalind Helen Gunby
Oncogenic Fusion Protein Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy
Haematologica 88:408-15. 2003..The expression of PDGFRbeta fusions in CMML could have therapeutic relevance, as PDGFRb is inhibited by the selective tyrosine kinase inhibitor, imatinib. Here, we investigated the possibility of employing imatinib to treat CMML... - Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patientsCarlo Gambacorti-Passerini
Department of Experimental Oncology, Istituto Nazionale Tumori, Milano, Italy
Clin Cancer Res 9:625-32. 2003..alpha1 acid glycoprotein (AGP) binds to imatinib with high affinity and inhibits imatinib activity in vitro and in vivo in an animal model. A pharmacokinetics analysis of imatinib was undertaken in CML patients... - Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclonesMarie Joelle Mozziconacci
Institut Paoli Calmettes and INSERM U119, Marseille, France
Genes Chromosomes Cancer 35:261-70. 2002..These data could focus further research for a better understanding of the molecular mechanisms underlying response or resistance to differentiating and/or apoptotic reagents... - Binding of imatinib by alpha(1)-acid glycoproteinCarlo Gambacorti-Passerini
Blood 100:367-8; author reply 368-9. 2002 - Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571Philipp Le Coutre
Abteilung für Hämatologie und Onkologie, Campus Virchow, Charite, Humboldt Universitat, Berlin, Germany
Blood Cells Mol Dis 28:75-85. 2002.... - Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz
M D Anderson Cancer Center, Houston, Texas, USA
Blood 99:1928-37. 2002..Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity... - Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian
M D Anderson Cancer Center, Houston, TX 77030, USA
N Engl J Med 346:645-52. 2002..Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase... - Gynaecomastia in men with chronic myeloid leukaemia after imatinibCarlo Gambacorti-Passerini
National Cancer Institute, Milan, Italy
Lancet 361:1954-6. 2003..36 pmol/L (-1.02 to 13.74). In most men with chronic myeloid leukaemia studied here, imatinib was associated with a reduction in the production of testicular hormones and in some, with the development of gynaecomastia... - Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivoAddolorata Maria Luce Coluccia
Department of Experimental Oncology, National Cancer Institute, Milan, Italy
Blood 103:2787-94. 2004..Bcl-XL deserves further investigation as a possible therapeutic target in ALK+ ALCLs... - Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levelsCarlo Gambacorti-Passerini
Blood 102:1933-4; author reply 1934-5. 2003 - Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patientSarit Assouline
Am J Hematol 81:646. 2006 - Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemiaSarit Assouline
N Engl J Med 354:2623-4. 2006 - An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinaseRosalind Helen Gunby
Haematologica 90:988-90. 2005..To this aim we have developed and optimized an ALK-specific enzyme-linked immunosorbent assay that employs a novel ALK peptide substrate and purified ALK kinase domain... - Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activityArianna Donella-Deana
Department of Biochemistry, University of Padova, Viale G Colombo 3, 35121 Padova, Italy
Biochemistry 44:8533-42. 2005..Such a peculiar substrate specificity allows the specific monitoring of ALK activity in crude extracts of NPM-ALK positive cells, using the YFF peptide, which is only marginally phosphorylated by a number of other tyrosine kinases... - Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatmentCarlo Gambacorti-Passerini
J Natl Cancer Inst 96:1723-4. 2004 - BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2Danilo Perrotti
Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Nat Genet 30:48-58. 2002..Our results indicate that BCR-ABL regulates the expression of C/EBPalpha by inducing hnRNP E2-which inhibits the translation of CEBPA mRNA... - ErbB-2 receptor cooperates with E6/E7 oncoproteins of HPV type 16 in breast tumorigenesisAmber Yasmeen
Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec H3T 1E2 Canada
Cell Cycle 6:2939-43. 2007..These findings provide evidence that the ErbB-2 receptor cooperates with high-risk HPVs in breast tumorigenesis via beta-catenin activation... - Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targetingIvan Plaza-Menacho
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, SW3 6JB London, United Kingdom
J Biol Chem 282:29230-40. 2007..In addition, because inhibition of RET is not impaired by mutation of the Val(804) gatekeeper residue, MEN2 tumors may be less susceptible to acquired Sorafenib resistance... - ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopesLorena Passoni
Oncogenic Fusion Genes and Proteins Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
Blood 99:2100-6. 2002.... - hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesisAngela Iervolino
Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Mol Cell Biol 22:2255-66. 2002..Together, these results suggest that the shuttling activity of hnRNP A1 is important for the nucleocytoplasmic trafficking of mRNAs that encode proteins influencing the phenotype of normal and BCR/ABL-transformed myeloid progenitors... - SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signalingAddolorata Maria Luce Coluccia
Department of Experimental Oncology, National Cancer Institute, Milan, Italy
Cancer Res 66:2279-86. 2006.... - Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesisAnna M Eiring
Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, USA
Blood 111:816-28. 2008..Thus, the complexity of the mRNA/RBP network, together with the discovery of E2F3 as an hnRNP-A1-regulated factor, outlines the relevant role played by RBPs in posttranscriptional regulation of CML development and progression... - Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cellsValentina Zuco
Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133, Milan, Italy
Cancer Lett 175:17-25. 2002..These data support further preclinical studies of betulinic acid not confined to melanoma and neuroectodermal tumors independently of p53 status...